PTC Therapeutics, Inc. (PTCT) Presents at Leerink Global Healthcare Conference 2026 Transcript

Core Insights - The company achieved significant revenue growth in 2025, driven by the launch of Sephience, a drug for PKU, generating over $111 million in revenue within the first 5.5 months [1] - The company ended 2025 with approximately $1.95 billion in cash, positioning itself well for future commercial and R&D initiatives [2] - Continued strong momentum is expected in the U.S. market, with revenue growth anticipated to be driven by Sephience throughout the year [3]